The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2024 | Components of the CAR-HEMATOTOX model which allow for prediction of ICAHT following CAR-T
Kai Rejeski, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the CAR-HEMATOTOX model, which aids in determining whether a patient receiving CAR T-cell therapy is at risk of developing immune effector cell-associated hematotoxicity (ICAHT). The five components of this model include absolute neutrophil count (ANC), hemoglobin levels, platelet count, and two indicators of baseline inflammation – C-reactive protein (CRP) and ferritin. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: BMS/CELGENE
Honoraria: BMS/CELGENE, Novartis
Travel Support: Kite/Gilead, Pierre-Fabre
Research Funding: Kite/Gilead
